MCM
SPRY icon

MAI Capital Management’s ARS Pharmaceuticals SPRY Stock Holding History

MAI Capital Management’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5
Closed -$41 – 4364
2026
Q1 		$41 Buy
+5
New +$48 ﹤0.01% 4891

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

MAI Capital Management's SPRY Position: Q2 2026 in Review

MAI Capital Management sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 5 shares — an estimated $41 sold.

MAI Capital Management first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $41 in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • MAI Capital Management reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 5 ARS Pharmaceuticals shares in Q2 2026, an estimated $41.
  • MAI Capital Management first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's ARS Pharmaceuticals position peaked at $41 in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.